Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional)
ID: 358369Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358369

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-300.html
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Jan 22, 2025, 12:00 AM UTC
  4. 4
    Due May 7, 2025, 12:00 AM UTC
Description

The National Institutes of Health (NIH) has announced a funding opportunity for the Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional), aimed at supporting research in the development and testing of behavioral treatments for substance misuse and dependence. This grant focuses on Stage I research, which includes the development and pilot testing of novel interventions or the refinement of existing treatments, with an emphasis on scalability and effectiveness in community applications. The initiative is crucial for advancing effective treatment methods for substance use disorders, ensuring they are robust and applicable to diverse populations. Eligible applicants can receive up to $450,000 for a three-year project period, with applications due by May 7, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-300.html.

Point(s) of Contact
grantsinfo@nih.gov
Files
Title
Posted
PAR-24-300-Full-Announcement.html
Jan 25, 2025, 12:05 PM UTC
PAR-24-300.html
Jan 25, 2025, 12:05 PM UTC
The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a Notice of Funding Opportunity (NOFO) for the Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional). This grant seeks to support research in developing and testing behavioral treatments for substance misuse and dependence. The focus is on generating novel interventions or refining existing ones, ideally to foster scalable and effective community applications. The grant includes three stages of research: Stage I (development and pilot testing), Stage II (efficacy testing), and Stage III (real-world efficacy testing), although this NOFO specifically supports only Stage I studies. Eligible applicants include various educational institutions, nonprofits, and governmental bodies, with up to $450,000 available for a three-year project period. Key research areas involve understanding mechanisms of behavior change, utilizing innovative technologies, and examining treatment adaptations for diverse populations. Applicants must comply with NIH submission processes and regulations, emphasizing rigorous scientific methods and the protection of human subjects. This initiative reflects NIDA’s commitment to advancing effective treatment methods for substance use disorders, ensuring they are robust and applicable to diverse community settings.
Similar Opportunities
Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled the Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional) aimed at advancing research in behavioral and integrative treatments for substance use and dependence. This program encourages the development and testing of innovative behavioral therapies through a structured approach that includes intervention generation, efficacy testing in research settings, and real-world efficacy assessments, with a focus on diverse populations and the use of technology. The funding amount is contingent on NIH appropriations, with a maximum project period of five years, and applications are due by February 5, 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-299.html.
Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances" under the R34 planning grant mechanism. This initiative aims to encourage formative research and the development of innovative interventions that target HIV prevention and care, particularly for populations that engage in substance use, addressing critical gaps in HIV care and prevention. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofit entities, and tribal governments, with grants available for up to $450,000 over three years. The application cycle begins on April 7, 2025, with subsequent due dates throughout the year, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
National Institutes of Health
The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment," aimed at encouraging clinical research to explore novel non-invasive brain stimulation (NIBS) targets for treating substance use disorders (SUD). This initiative seeks applications for exploratory and developmental studies that will identify and validate neurobiological, cognitive, and behavioral responses to NIBS, with the goal of understanding mechanisms that could lead to reduced cravings and substance use. The NIH plans to allocate $1.5 million in funding for fiscal years 2024-2026, with an award ceiling of $500,000 per project phase, and key submission dates starting December 16, 2023. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders" (R34 Clinical Trial Optional). This initiative encourages pilot studies aimed at preparing for larger-scale effectiveness trials that focus on optimizing access, quality, and affordability of substance use disorder treatments and related services, with an emphasis on diverse perspectives through a Plan for Enhancing Diverse Perspectives (PEDP). Applicants may request up to $450,000 in direct costs for a three-year grant, with application due dates beginning January 16, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-100.html.
Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)" aimed at advancing clinical research in the field of substance use disorders (SUD). The primary objective is to identify and validate novel targets for non-invasive brain stimulation (NIBS) and to explore the neurobiological, cognitive, and behavioral responses associated with NIBS that may lead to improved clinical outcomes such as reduced cravings or drug use. This initiative is crucial for enhancing understanding and treatment options for SUD through innovative research methodologies. Funding of up to $1.5 million is available for selected projects over a maximum project period of five years, with applications due by August 14, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the detailed application instructions available at the provided link.
Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials," aimed at encouraging pilot research to develop and test interventions that prevent or delay substance use. The initiative focuses on the creation and pilot testing of new or adapted strategies to curb substance misuse, particularly among underserved populations, while also addressing related negative outcomes such as impaired driving and transmission of infectious diseases. Eligible applicants include a wide range of institutions, such as academic, nonprofit, and government organizations, with funding available up to $450,000 over three years. Interested parties should note that applications are due starting January 16, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications that support a diverse range of preclinical and clinical projects, with the goal of advancing medication studies toward FDA approval, emphasizing the importance of innovative approaches to drug misuse and addiction treatment. Eligible applicants include a variety of institutions, such as higher education entities and community organizations, with funding available up to $5 million per year for projects lasting up to three years. Interested parties can find more information and submit inquiries via grantsinfo@nih.gov, with applications due by August 11, 2025.
Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional)" aimed at encouraging clinical research to identify and validate novel targets for non-invasive brain stimulation (NIBS) related to substance use disorders (SUD). This initiative seeks exploratory and developmental studies that may involve significant risks but have the potential to lead to breakthroughs in understanding the neurobiological and behavioral responses associated with SUD treatment. The funding opportunity includes a budget cap of $600,000 for the R61 phase, with a total of up to $1.5 million available across multiple awards, and requires applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP). Interested applicants should note that the application period opens on December 16, 2023, and closes on August 14, 2026; for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov.
Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity for the development of medications aimed at preventing and treating substance use disorders (SUDs) and overdose. This initiative is structured into two phases: the UG3 phase focuses on achieving specific milestones within a two-year period, while the UH3 phase extends support for an additional three years for projects that successfully meet the UG3 milestones. Given the urgent need for effective treatments in light of rising overdose deaths, particularly from synthetic opioids and stimulants, this funding opportunity emphasizes innovative research methodologies and the effective application of existing medications. Interested applicants can seek funding of up to $3 million annually for a maximum of five years, with applications due by August 11, 2025. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-329.html.